The addition of neprilysin inhibition to standard therapy, including a renin-angiotensin system blocker, has been demonstrated to improve outcomes in patients with heart failure with reduced ejection fraction (HFrEF) compared with standard therapy alone. The long-term absolute risk reduction from angiotensin receptor-neprilysin inhibitor (ARNI) therapy, and whether it merits widespread use among diverse subpopulations, has not been well described. 
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I n the Prospective Comparison of Angiotensin ReceptorNeprilysin Inhibitor (ARNI) with Angiotensin-Converting Enzyme Inhibitor (ACEI) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, randomization to sacubitril-valsartan vs enalapril led to a 20% relative risk reduction in the primary outcome of death from cardiovascular causes or first hospitalization for worsening heart failure (HF) among patients with heart failure with reduced ejection fraction (HFrEF) over a median follow-up of 27 months. 1 While short-term risk reductions for the overall PARA-DIGM-HF cohort have been reported, absolute risk reduction and number needed to treat (NNT) values for long-term (5-year) follow-up have not. Here, we report estimated multiyear, long-term NNT values for neprilysin inhibition added to standard therapy including renin-angiotensin system (RAS) blockade (ARNI incremental to ACEI) compared with standard therapy with RAS blockade alone and for a neprilysin inhibitor combined with a RAS blocker (ARNI) compared with imputed placebo for the overall patient population as well as for clinically relevant subpopulations in PARADIGM-HF and compare them with those for other well-established HFrEF therapies.
Methods
PARADIGM-HF was a double-blind, randomized clinical trial of sacubitril-valsartan vs enalapril in 8399 men and women with HFrEF (ejection fraction, ≤40%). The primary end point was death from cardiovascular causes or first hospitalization for worsening HF. Full details of the study have been previously described. 1 The trial was approved by the ethics committee at each study center. All enrolled patients provided written informed consent. The study took place from December 2009 to March 2014, and analyses began in March 2018. In PARADIGM-HF, NNT values for ARNI therapy incremental to ACEI therapy were estimated for trial years 1 to 5 for the primary end point as well as for the end points of death from cardiovascular causes and for all-cause mortality. The NNT values were estimated as the inverse of the difference in estimated absolute risk between the enalapril and ARNI groups at each time point. For years 1 to 3, absolute risk for the enalapril group was calculated directly from Kaplan-Meier estimates. For years 4 and 5, absolute risk in the enalapril group was projected by first calculating annualized incidence rates (incident events per patientyear) during the first year of follow-up postrandomization (r1) and separately for follow-up beyond the first year (r2). The cumulative risk at year 4 was then estimated as 1 year of exposure to the first-year incidence rate followed by 3 years of exposure to the subsequent incidence rate (ie, 4-year cumulative risk=1−exp[−{r1+3×r2}]). Absolute risk for the ARNI group was estimated by applying the end point-specific hazard ratio (HR) (ie, Risk ARNI =1−exp[log{1 − Risk ENALAPRIL } × HR]) at each time point. Number needed to treat values for ARNI therapy compared with imputed placebo were similarly calculated using data from a previously published ARNI vs imputed placebo analysis from PARADIGM-HF. 2 Five-year NNT values for other HFrEF therapies were estimated by taking the inverse of the difference in 5-year absolute risk between original trial intervention and control groups for the outcome of all-cause mortality. Five-year risks were estimated using previously published data on event rates with the assumption that all-cause mortality rates and treatment effects were constant after trial conclusion. [2] [3] [4] [5] [6] [7] [8] All statistical analysis was performed using STATA (version 14).
Results
The mean (SD) age of the randomized cohort was 63.8 (11.4) years. Of 8399 individuals, 1832 (21.8%) were women and 5544 (66.0%) were white. Initial trial event and incident rates, as well as NNT values for the overall cohort by year, are displayed in Table 1 . The 5-year estimated NNT with ARNI therapy incremental to ACEI for the study's primary end point was 14. The 5-year estimated NNT values for the end points of cardiovascular death and all-cause mortality were 19 and 21, respectively. The 5-year estimated NNT values for different subgroups are shown in Table 2 . Values ranged from 12 to 19 among the different groups for the study's primary end point, from 14 to 31 for the end point of any cardiovascular death, and from 16 to 31 for the end point of all-cause mortality.
The 5-year estimated NNT with ARNI therapy compared with imputed placebo for the study's primary end point and the end points of cardiovascular death and all-cause mortality were 5, 9, and 11, respectively (Table 1) . Five-year estimated NNT values for ARNI compared with placebo for different subgroups in PARADIGM-HF are shown in the eTable in the Supplement.
The 5-year estimated NNT values for other wellestablished HFrEF therapies, compared with control, from selected landmark clinical trials are shown in Table 3 . For the end
Key Points
Question What is the long-term absolute risk reduction from adding a neprilysin inhibitor to standard therapy, including a renin-angiotensin system blocker, in patients with heart failure with reduced ejection fraction (HFrEF) for cardiovascular death or HF hospitalization and all-cause mortality as quantified by number needed to treat (NNT)?
Findings In this study, the 5-year estimated NNT for the primary outcome of cardiovascular death or HF hospitalization with angiotensin receptor-neprilysin inhibitor therapy incremental to angiotensin-converting enzyme inhibitor was 14 in the overall cohort and ranged from 12 to 19 among different subpopulations. The 5-year estimated NNT was 21 for all-cause mortality incremental to angiotensin-converting enzyme inhibitor and 11 for all-cause mortality when compared with imputed placebo.
Meaning
The 5-year estimated NNT with adding a neprilysin inhibitor to standard therapy, including a renin-angiotensin system blocker for HFrEF, overall and for clinically relevant subpopulations are comparable with those estimated for other well-established HF therapies, supporting current guideline recommendations for use of angiotensin receptor-neprilysin inhibitor therapy among eligible patients.
point of all-cause mortality, the 5-year estimated NNT values were 18 for ACEI, 24 for angiotensin receptor blockers, 8 for β-blockers, 15 for mineralocorticoid antagonists, 14 for implantable cardioverter defibrillator, and 14 for cardiac resynchronization therapy.
Discussion
In this analysis of PARADIGM-HF, we present overall and for clinically relevant subpopulations, the 1-to 5-year estimated NNT values for the addition of neprilysin inhibitor therapy to standard background therapy for the end points of cardiovascular death or hospitalization for HF, any cardiovascular death, and all-cause mortality. The 5-year estimated NNT for ARNI therapy incremental to ACEI therapy was 14 for the primary end point of cardiovascular death or hospitalization for HF and 21 for the end point of all-cause mortality. The 5-year estimated NNTs across clinically relevant subgroups were all in a relatively narrow range, reflecting the lack of significant heterogeneity in clinical benefits of ARNI therapy across different subpopulations.
In our analysis, we demonstrate 5-year estimated NNT values of 12 to 31 for ARNI therapy incremental to ACEI therapy overall and among diverse clinically relevant subgroups of patients with HFrEF across a range of end points including all-cause mortality, cardiovascular mortality, and hospitalization for HF. These 5-year values are similar to or better than currently well-accepted therapies for cardiovascular disease. For example, aspirin for primary prevention has a 5-year estimated NNT of 346 in men and 426 in women for the end point of myocardial infarction, stroke, or cardiovascular death. 9, 10 Statins for primary prevention have a 5-year NNT ranging from 20 to 63 across a variety of end points including myocardial infarction, stroke, and allcause mortality. 9,11 These 5-year estimated NNT values for ARNI therapy are comparable with other well-established HFrEF therapies compared with placebo with background therapy standard at the time for the end point of all-cause mortality.
Neprilysin inhibitor therapy has the potential to significantly impact cardiovascular morbidity and mortality among patients with HFrEF. Cost-effectiveness analyses of ARNI therapy have found it to have an incremental cost per quality-adjusted life-year of $45 000 to $50 000. 12, 13 We previously reported an anticipated yearly reduction of 28 484 deaths with optimal implementation of ARNI therapy in the United States, and other data have demonstrated an estimated extension of 1 to 2 years in mean survival with ARNI use compared with ACEI therapy as well as improvement in quality of life. [14] [15] [16] Our analysis adds to this work by providing 5-year estimated NNTs that further quantify long-term benefit of ARNI therapy incremental to ACEI overall and among diverse patient subpopulations. Taken together, these results further support current guidelines recommendations for optimal implementation of ARNI therapy among eligible patients with HFrEF.
Limitations
This analysis is limited by the methodology used to calculate 5-year estimated NNT values. For patients in PARADIGM-HF, absolute risk at 4 and 5 years had to be projected using risk from years 1 to 3 given the smaller sample size available at years 4 and 5. To the extent that actual risk differences may vary from this assumption, the NNT values overall and for subpopulations would also differ. Given this limitation, we recommend caution when interpreting subgroup results, although it should be noted that the subpopulations were prespecified and that the NNT values were projected directly from observed event rates in these particular groups during the course of the trial. Direct study data at 5 years were not available for the other reported HFrEF therapies, and so absolute risk at 5 years was estimated by extrapolating published trial data with the assumption that all-cause mortality rates and treatment effects were constant after study completion. Our comparison of ARNI therapy incremental to ACEI to other HF therapies is limited by the difference in trial patient populations and by the difference in baseline goal-directed medical therapy available at the time of each study.
Conclusions
The 5-year estimated NNT values for adding a neprilysin inhibitor to standard therapy, including a RAS blocker, among patients with HFrEF overall and for clinically relevant subpopulations are comparable with those of other wellestablished HF interventions and are better than those of commonly prescribed drugs for primary prevention. These data support the current guidelines recommendations for ARNI therapy for eligible patients with HFrEF. MAGGIC, Meta-Analysis Global Group in Chronic Heart Failure NT-proBNP, N-terminal pro-B-type Natriuretic Peptide
